A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.
Colorectal cancer remains the third most common malignancy worldwide, with advanced stages presenting significant challenges for treatment. A recently published study highlights the potential of combining the antiangiogenic peptide TB-01 (PEP-06), a drug in phase II studies in China, with the approved cytotoxic drug trifluridine/tipiracil (TAS-102) as a treatment for colorectal cancer.
Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the original PDX tumor characteristics.
Oxford Drug Design Ltd. has announced additional in vivo validation for its novel approach against cancer. The innovative approach, using generative AI capabilities, is based on the novel target leucyl-tRNA synthetase.
Vir Biotechnology Inc.’s 2024 deal with Sanofi SA is starting to look like a pretty savvy move. The company, which picked up three clinical-stage dual-masked T-cell engagers (TCEs) and rights to the platform technology as part of a pipeline overhaul, reported phase I data for TCE programs targeting HER2 and PSMA that indicated promising efficacy with a low prevalence of the cytokine toxicity that has hampered other TCE programs.
CSPC Pharmaceutical Group Ltd.’s antibody-drug conjugate SYS-6045 has been granted clearance by China’s National Medical Products Administration (NMPA) to enter clinical trials.
The company analyzed genomic data provided by the Fred Hutch Cancer Center and compiled by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) to identify mutational signatures and single nucleotide polymorphisms (SNPs) predictive of colorectal cancer.
When it comes to cell therapy, Alloplex Biotherapeutics Inc. CEO Frank Borriello said he believes that autologous, personalized therapy is the only thing that makes sense. “The allure of an off-the-shelf therapy has been such a magnet. It sucked in a lot of companies into that dream, and I'm sorry to say, it hasn't really worked out for them,” he told BioWorld. Instead, Borriello said he envisioned a cell training platform that doesn’t just tweak a single immune pathway but instead harnesses multiple immune pathways to turn the tables on cancer.
